Sample demographics and clinical characteristics
| . | SCT (n = 31) . | Non-SCT (n = 110) . | Total sample (n = 141) . |
|---|---|---|---|
| Child characteristics | |||
| Site of care | |||
| Boston, n (%) | 24 (77) | 78 (71) | 102 (72) |
| Minneapolis/St Paul, n (%) | 7 (23) | 32 (29) | 39 (28) |
| Female sex, n (%) | 15 (48) | 51 (46) | 66 (47) |
| Mean age at death, y (SD) | 9.3 (6.9) | 10.5 (6.5) | 10.3 (6.6) |
| Mean time since death, y (SD) | 3.5 (2.0) | 3.8 (2.2) | 3.7 (2.2) |
| Parent characteristics | |||
| Female sex, n (%) | 26 (84) | 91 (82) | 117 (83) |
| Mean age at child's death, y (SD) | 41.9 (7.8) | 43.5 (7.8) | 43.1 (7.7) |
| White race, n (%) | 29 (94) | 102 (93) | 131 (93) |
| Postsecondary education, n (%) | 23 (74) | 86 (78) | 109 (77) |
| Annual income < $50 000, n (%) | 14 (45) | 53 (49) | 67 (48) |
| Disease characteristics | |||
| Mean duration of illness, y (SD) | 3.0 (4.1) | 2.6 (2.9) | 2.7 (3.2) |
| Cancer type | |||
| Hematologic malignancy, n (%) | 27 (87) | 43 (39) | 70 (50) |
| Solid/brain tumor, n (%) | 4 (13) | 67 (61) | 71 (50) |
| . | SCT (n = 31) . | Non-SCT (n = 110) . | Total sample (n = 141) . |
|---|---|---|---|
| Child characteristics | |||
| Site of care | |||
| Boston, n (%) | 24 (77) | 78 (71) | 102 (72) |
| Minneapolis/St Paul, n (%) | 7 (23) | 32 (29) | 39 (28) |
| Female sex, n (%) | 15 (48) | 51 (46) | 66 (47) |
| Mean age at death, y (SD) | 9.3 (6.9) | 10.5 (6.5) | 10.3 (6.6) |
| Mean time since death, y (SD) | 3.5 (2.0) | 3.8 (2.2) | 3.7 (2.2) |
| Parent characteristics | |||
| Female sex, n (%) | 26 (84) | 91 (82) | 117 (83) |
| Mean age at child's death, y (SD) | 41.9 (7.8) | 43.5 (7.8) | 43.1 (7.7) |
| White race, n (%) | 29 (94) | 102 (93) | 131 (93) |
| Postsecondary education, n (%) | 23 (74) | 86 (78) | 109 (77) |
| Annual income < $50 000, n (%) | 14 (45) | 53 (49) | 67 (48) |
| Disease characteristics | |||
| Mean duration of illness, y (SD) | 3.0 (4.1) | 2.6 (2.9) | 2.7 (3.2) |
| Cancer type | |||
| Hematologic malignancy, n (%) | 27 (87) | 43 (39) | 70 (50) |
| Solid/brain tumor, n (%) | 4 (13) | 67 (61) | 71 (50) |
There were no significant differences between the stem cell transplantation (SCT) and the non-SCT groups other than diagnosis. Those in the SCT group were more likely to have had a hematologic malignancy than a solid/brain tumor (P < .001).